Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Jade Biosciences, Inc.AVTE · Entity 4757 | SEE REMARKS | July 31, 2024 | August 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Jade Biosciences, Inc.
Report date July 31, 2024 · Filed August 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,252 |
Ending reported balance
After 2024-08-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-07-31 · Exercise / conversion · Acquired 11,454 · Balance 12,745 Row 2 · 2024-08-01 · Exercise / conversion · Acquired 1,507 · Balance 14,252 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 0 |
Reported balance
After 2024-07-31 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-07-31 · Exercise / conversion · Disposed 906 · Balance 0 F1: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 1,507 |
Reported balance
After 2024-07-31 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-07-31 · Exercise / conversion · Disposed 10,548 · Balance 1,507 F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.74 · Expires 2030-09-03 | Direct | 0 |
Reported balance
After 2024-08-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-08-01 · Exercise / conversion · Disposed 1,507 · Balance 0 F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
F2: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 01, 2024 Filed Aug 2, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-24-020662 · form4-08022024_060818.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,507 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| August 01, 2024 Filed Aug 2, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 1,507 | $1.74 | $2,622.18 |
DisclosureSEC source: 0001415889-24-020662 · form4-08022024_060818.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,252 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,548 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-24-020662 · form4-08022024_060818.xml · derivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,507 Underlying: Common Stock · 10,548 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 906 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-24-020662 · form4-08022024_060818.xml · derivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 906 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| July 31, 2024 Filed Aug 2, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 11,454 | $1.74 | $19,929.96 |
DisclosureSEC source: 0001415889-24-020662 · form4-08022024_060818.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,853 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-011252 · form4-04192024_060407.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 95,936 Underlying: Common Stock · 6,853 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F4 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 68 | $23.97 | $1,629.96 |
DisclosureSEC source: 0001415889-24-011252 · form4-04192024_060407.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 338 | $23.17 | $7,831.43 |
DisclosureSEC source: 0001415889-24-011252 · form4-04192024_060407.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,359 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.825 to $23.65, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 6,447 | $22.32 | $143,865.45 |
DisclosureSEC source: 0001415889-24-011252 · form4-04192024_060407.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,697 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.812 to $22.80, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 17, 2024 Filed Apr 19, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 6,853 | $2.14 | $14,665.42 |
DisclosureSEC source: 0001415889-24-011252 · form4-04192024_060407.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,325 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001415889-24-010137 · form4-04032024_060406.xml · derivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,675 Underlying: Common Stock · 3,325 shares Expires 2031-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F3 · derivative.exercise_date: A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,325 | $31.97 | $106,316.54 |
DisclosureSEC source: 0001415889-24-010137 · form4-04032024_060406.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $31.95 to $32.415, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 3,325 | $10.61 | $35,278.25 |
DisclosureSEC source: 0001415889-24-010137 · form4-04032024_060406.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,616 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. Read SEC document |
| March 27, 2024 Filed Mar 28, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 11,068 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001415889-24-009364 · form4-03282024_060301.xml · derivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,000 Underlying: Common Stock · 11,068 shares Expires 2031-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F3 · derivative.exercise_date: A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| March 27, 2024 Filed Mar 28, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 11,068 | $27.97 | $309,518.83 |
DisclosureSEC source: 0001415889-24-009364 · form4-03282024_060301.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.95 to $28.18, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 27, 2024 Filed Mar 28, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 11,068 | $10.61 | $117,431.48 |
DisclosureSEC source: 0001415889-24-009364 · form4-03282024_060301.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,432 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001415889-24-009243 · form4-03272024_060301.xml · derivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,068 Underlying: Common Stock · 3,432 shares Expires 2031-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F3 · derivative.exercise_date: A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 3,432 | $28.01 | $96,119.34 |
DisclosureSEC source: 0001415889-24-009243 · form4-03272024_060301.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $27.95 to $28.385, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 25, 2024 Filed Mar 27, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 3,432 | $10.61 | $36,413.52 |
DisclosureSEC source: 0001415889-24-009243 · form4-03272024_060301.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 14,500 | $0.00 Strike: $10.61 | $0.00 |
DisclosureSEC source: 0001415889-24-008770 · form4-03202024_060307.xml · derivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 43,500 Underlying: Common Stock · 14,500 shares Expires 2031-12-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F5 · derivative.exercise_date: A total of 58,000 shares subject to an employee stock option were granted on December 14, 2021, with the first installment vested on January 14, 2022, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,557 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-24-008770 · form4-03202024_060307.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,789 Underlying: Common Stock · 20,557 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F4 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 7,581 | $26.48 | $200,763.83 |
DisclosureSEC source: 0001415889-24-008770 · form4-03202024_060307.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.25 to $26.88, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 27,476 | $25.74 | $707,281.70 |
DisclosureSEC source: 0001415889-24-008770 · form4-03202024_060307.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,872 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.235 to $26.234, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 14,500 | $10.61 | $153,845.00 |
DisclosureSEC source: 0001415889-24-008770 · form4-03202024_060307.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 36,348 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 20,557 | $2.14 | $43,991.98 |
DisclosureSEC source: 0001415889-24-008770 · form4-03202024_060307.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,848 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 16, 2023. Read SEC document |
| January 22, 2024 Filed Jan 24, 2024 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | GrantStock Options (Right to Buy) · Derivative | 66,586 | $0.00 Strike: $20.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001773 · form4-01242024_060101.xml · derivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,586 Underlying: Common Stock · 66,586 shares Expires 2034-01-21 F1 · derivative.exercise_date: This option shall vest and become exercisable in 48 substantially equal monthly installments, with the first installment vesting on February 22, 2024. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,853 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-015986 · form4-12072023_061201.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 123,346 Underlying: Common Stock · 6,853 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,019 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-015986 · form4-12072023_061201.xml · derivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,294 Underlying: Common Stock · 1,019 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,506 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-015986 · form4-12072023_061201.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 12,055 Underlying: Common Stock · 1,506 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 905 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-015986 · form4-12072023_061201.xml · derivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 906 Underlying: Common Stock · 905 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 10,283 | $16.11 | $165,628.28 |
DisclosureSEC source: 0001415889-23-015986 · form4-12072023_061201.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.71 to $16.455, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 7,872 | $2.14 | $16,846.08 |
DisclosureSEC source: 0001415889-23-015986 · form4-12072023_061201.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,574 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| December 06, 2023 Filed Dec 7, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,411 | $1.74 | $4,195.14 |
DisclosureSEC source: 0001415889-23-015986 · form4-12072023_061201.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,702 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 9,086 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-015599 · form4-11292023_061101.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,199 Underlying: Common Stock · 9,086 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,018 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-015599 · form4-11292023_061101.xml · derivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,313 Underlying: Common Stock · 1,018 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-015599 · form4-11292023_061101.xml · derivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,561 Underlying: Common Stock · 1,507 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 906 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-015599 · form4-11292023_061101.xml · derivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,811 Underlying: Common Stock · 906 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 12,517 | $16.24 | $203,237.28 |
DisclosureSEC source: 0001415889-23-015599 · form4-11292023_061101.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.635 to $16.58, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 10,104 | $2.14 | $21,622.56 |
DisclosureSEC source: 0001415889-23-015599 · form4-11292023_061101.xml · nonDerivative · entry 2 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,808 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| November 27, 2023 Filed Nov 29, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 2,413 | $1.74 | $4,198.62 |
DisclosureSEC source: 0001415889-23-015599 · form4-11292023_061101.xml · nonDerivative · entry 1 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 3,704 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| November 24, 2023 Filed Nov 27, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,619 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-015509 · form4-11272023_061104.xml · derivative · entry 12 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,285 Underlying: Common Stock · 4,619 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F8 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| November 24, 2023 Filed Nov 27, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 371 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-015509 · form4-11272023_061104.xml · derivative · entry 11 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,331 Underlying: Common Stock · 371 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| November 24, 2023 Filed Nov 27, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 70 | $16.07 | $1,124.59 |
DisclosureSEC source: 0001415889-23-015509 · form4-11272023_061104.xml · nonDerivative · entry 6 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.035 to $16.11, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 24, 2023 Filed Nov 27, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 4,920 | $15.74 | $77,423.09 |
DisclosureSEC source: 0001415889-23-015509 · form4-11272023_061104.xml · nonDerivative · entry 5 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,361 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.034 to $16.025, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 24, 2023 Filed Nov 27, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionCommon Stock | 4,990 | $2.14 | $10,678.60 |
DisclosureSEC source: 0001415889-23-015509 · form4-11272023_061104.xml · nonDerivative · entry 4 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,281 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,322 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-015509 · form4-11272023_061104.xml · derivative · entry 10 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 143,904 Underlying: Common Stock · 6,322 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F8 · derivative.exercise_date: A total of 328,921 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on July 4, 2021, and with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 648 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001415889-23-015509 · form4-11272023_061104.xml · derivative · entry 9 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,702 Underlying: Common Stock · 648 shares Expires 2031-04-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F7 · derivative.exercise_date: A total of 48,882 shares subject to an employee stock option were granted on April 2, 2021, with the first installment vested on May 2, 2021, with shares vesting in 48 substantially equal monthly installments. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,507 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-015509 · form4-11272023_061104.xml · derivative · entry 8 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,068 Underlying: Common Stock · 1,507 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F6 · derivative.exercise_date: A total of 72,325 shares subject to an employee stock option were granted on September 4, 2020, with 25% of the shares vested on August 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | Exercise / conversionStock Option (Right to Buy) · Derivative | 905 | $0.00 Strike: $1.74 | $0.00 |
DisclosureSEC source: 0001415889-23-015509 · form4-11272023_061104.xml · derivative · entry 7 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,717 Underlying: Common Stock · 905 shares Expires 2030-09-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F5 · derivative.exercise_date: A total of 48,293 shares subject to an employee stock option were granted on September 4, 2020, with 10% of the shares vested on January 1, 2020, an additional 22.5% of the shares vested on January 1, 2021, and the remainder vesting in 36 substantially equal monthly installments thereafter. Read SEC document |
| November 22, 2023 Filed Nov 27, 2023 18:00 UTC | Jade Biosciences, Inc. AVTE · Entity 4757 | SaleCommon Stock | 9,382 | $15.17 | $142,358.72 |
DisclosureSEC source: 0001415889-23-015509 · form4-11272023_061104.xml · nonDerivative · entry 3 Dake Benjamin T · CIK 0001869248 · SEE REMARKS 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,291 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 14, 2022. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $15.00 to $15.37, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.